Ninety One UK Ltd Buys 21,041 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ninety One UK Ltd grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 42.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,032 shares of the company’s stock after acquiring an additional 21,041 shares during the period. Ninety One UK Ltd owned about 0.09% of IDEXX Laboratories worth $29,367,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. International Assets Investment Management LLC grew its position in shares of IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after acquiring an additional 527,460 shares during the period. Assenagon Asset Management S.A. grew its position in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after acquiring an additional 316,048 shares during the period. Seilern Investment Management Ltd bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $113,104,000. Vontobel Holding Ltd. boosted its holdings in IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after buying an additional 213,731 shares during the period. Finally, Worldquant Millennium Advisors LLC boosted its holdings in IDEXX Laboratories by 230.1% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock worth $55,673,000 after buying an additional 76,809 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $468.55 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The stock has a market capitalization of $38.37 billion, a PE ratio of 45.18, a P/E/G ratio of 3.64 and a beta of 1.37. The company’s 50 day simple moving average is $425.88 and its two-hundred day simple moving average is $453.51.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of several analyst reports. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $524.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.